A half-dozen companies dominate AI scribe contracts with health systems, including Microsoft’s Nuance, Nabla, and Epic-partnered Abridge.

Four pharmaceutical companies involved in the negotiations over prices for Medicare do not expect a significant impact on their businesses after seeing confidential suggested prices.

Sarepta Therapeutics demanded a prominent patient advocacy organization censor a video containing pointed criticism of its new gene therapy for Duchenne muscular dystrophy.

A European Medicines Agency committee that evaluates new drugs recommended that Leqembi, an Alzheimer’s therapy from Eisai and Biogen, should be rejected.

Viking Therapeutics plans to move its injectable obesity treatment into a Phase 3 study faster than expected, bringing it closer to joining the highly competitive GLP-1 drug market.

CVS Caremark, one of the largest PBMs, agreed to pay at least $45 million to the state of Illinois to settle allegations that rebates were not passed through.

A U.S. House investigation found PBMs promise to control costs, but have instead steered patients toward higher-priced medicines and affiliated pharmacies — steps that increase spending.

Express Scripts, one of the largest PBMs, overcharged U.S. Postal Service workers by $45 million for prescription drugs during a recent five-year period.

Eli Lilly said its weight loss drug tirzepatide won approval in China, intensifying competition with Novo Nordisk in the key Asian market.

Gilead Sciences’ chief medical officer will leave early next year as the drugmaker struggles to find new areas of growth beyond its core HIV medicines

The Broad Data Science Platform's 250 employees are anxious about their future following leadership changes in the division.

Increasing rigor, and better evidence, can help digital therapeutics companies convince critics that their novel treatments are valuable.

Roche reported positive early data from an obesity drug candidate, bolstering the case it could become a player in the competitive weight loss medicine field.

A Senate bill was touted as a cure for "patent thickets." Some say the drug industry watered it down.

Vertex Pharmaceuticals filed a lawsuit to make it possible to pay for fertility preservation services and treatment for people receiving its Casgevy sickle cell disease therapy.

Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the U.S.

Novo Nordisk's Ozempic was linked to lower rates of dementia and other mental problems in a study that raises expectations about its potential ancillary benefits.

The FDA rejected Novo Nordisk’s weekly insulin for treating diabetes in a rare setback for the company.

Biopharma layoffs have been higher over the past couple of years than during the industry’s boom times amid the pandemic; job cuts this year have mainly hit larger pharmaceutical companies.

Continued growth and investor interest in creating novel neurotherapeutics hinge on their ability to adapt, pivot quickly, and embrace new approaches and development models.

In stark terms, the Federal Trade Commission released a report describing pharmacy benefit managers as wielding “enormous power.”

AbbVie paid health care providers roughly $145.7 million last year to promote its drugs, the most a company has spent since such data became available.

A study reported for the first time a potential link between Novo Nordisk's GLP-1 drugs and an eye condition that can cause vision loss.

GSK reached a licensing agreement with mRNA-vaccine developer CureVac worth up to $1.8 billion to develop its vaccines for seasonal flu, Covid-19, and avian flu.

The unilateral decision by Peter Marks, a top FDA official, to approve a gene therapy for Duchenne muscular dystrophy looks even more surprising on a close examination.

Moderna will receive $176 million from HHS' BARDA to accelerate development of mRNA-based pandemic influenza vaccines, the company said Tuesday.

The FTC is investigating Teva Pharmaceuticals after it refused to remove about two dozen patents for asthma and COPD inhalers from a federal registry.

The owners of a drug wholesaler have been indicted for their alleged role in a conspiracy to distribute misbranded and diverted HIV pills.

An enormous experiment by Medicare shows a null effect: Financial incentives haven't gotten dialysis providers to move more patients to home dialysis or transplant. 

Psychedelic evangelists have been working to win over regulators since the 1980s, and those relationships helped persuade the FDA to sign off on research.